Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:49:17.524Z.
Calculation as of: 2026-10-06T19:49:17.524Z.
Quote observation: 2026-10-06T19:45:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$261.58M
EV/Sales Ratio
62.21x
TTM Avg
74.23x
3Y Avg
31.36x
5Y Avg
21.18x
Market Cap
$261.10M
EV/Sales Ratio
271.85x
TTM Avg
543.80x
3Y Avg
374.50x
5Y Avg
374.50x
Market Cap
$263.41M
EV/Sales Ratio
N/A
TTM Avg
8390802.46x
3Y Avg
5153796.41x
5Y Avg
3581310.58x
Market Cap
$260.59M
EV/Sales Ratio
1.00x
TTM Avg
0.74x
3Y Avg
0.47x
5Y Avg
0.82x
Market Cap
$263.71M
EV/Sales Ratio
1.58x
TTM Avg
1.20x
3Y Avg
2.37x
5Y Avg
5.33x
Market Cap
$259.30M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.91M
EV/Sales Ratio
8.90x
TTM Avg
17.11x
3Y Avg
33.44x
5Y Avg
33.44x
Market Cap
$266.62M
EV/Sales Ratio
5.65x
TTM Avg
5.31x
3Y Avg
6.28x
5Y Avg
18.29x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $262.47M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $261.58M | 62.21x | 74.23x | 31.36x | 21.18x |
| Palisade Bio, Inc. (PALI)vs › | $261.10M | 271.85x | 543.80x | 374.50x | 374.50x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.41M | N/A | 8390802.46x | 5153796.41x | 3581310.58x |
| OraSure Technologies, Inc. (OSUR)vs › | $260.59M | 1.00x | 0.74x | 0.47x | 0.82x |
| Treace Medical Concepts, Inc. (TMCI)vs › | $263.71M | 1.58x | 1.20x | 2.37x | 5.33x |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $258.91M | 8.90x | 17.11x | 33.44x | 33.44x |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.62M | 5.65x | 5.31x | 6.28x | 18.29x |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.34M | N/A | 495.70x | 495.70x | 495.70x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
